Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGI

Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical trial with no observed safety concerns when compared to the placebo group.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3zAkSUV
via IFTTT